Logo image of PRE

PRENETICS GLOBAL LTD-CL A (PRE) Stock Price, Quote, News and Overview

NASDAQ:PRE - Nasdaq - KYG722451229 - Common Stock - Currency: USD

5.3877  +0.2 (+3.81%)

PRE Quote, Performance and Key Statistics

PRENETICS GLOBAL LTD-CL A

NASDAQ:PRE (5/9/2025, 4:30:00 PM)

5.3877

+0.2 (+3.81%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Providers & Services
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Services
Statistics
52 Week High6.99
52 Week Low3.09
Market Cap65.84M
Shares12.22M
Float8.36M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO07-06 2021-07-06


PRE short term performance overview.The bars show the price performance of PRE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40 50

PRE long term performance overview.The bars show the price performance of PRE in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PRE is 5.3877 USD. In the past month the price increased by 51.4%. In the past year, price decreased by -8.95%.

PRENETICS GLOBAL LTD-CL A / PRE Daily stock chart

PRE Competitors/Peers

The largest stocks on the US markets in the "Health Care Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
CI THE CIGNA GROUP 12.08 90.40B
CVS CVS HEALTH CORP 10.53 84.54B
LH LABCORP HOLDINGS INC 16.68 20.57B
DGX QUEST DIAGNOSTICS INC 19.26 19.76B
FMS FRESENIUS MEDICAL CARE-ADR 17.86 16.66B
BTSGU BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 129.32 14.04B
HIMS HIMS & HERS HEALTH INC 75.3 11.62B
DVA DAVITA INC 15.13 11.05B
CHE CHEMED CORP 24.19 8.34B
CRVL CORVEL CORP 26.92 5.78B
OPCH OPTION CARE HEALTH INC 23.41 5.21B
GH GUARDANT HEALTH INC N/A 5.17B

About PRE

Company Profile

PRE logo image Prenetics Global Limited is a health sciences company, which engages in the provision of early detection, prevention, and treatment of cancer. The company employs 320 full-time employees The company went IPO on 2021-07-06. The firm operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The firm's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The firm is also engaged in consumer health products by a new health and wellness brand IM8.

Company Info

PRENETICS GLOBAL LTD-CL A

Unit 703-706, K11 Atelier King's Road, 728 King's Road, Quarry Bay

Hong Kong HM 08 HK

CEO: David Zwiener

Employees: 322

PRE Company Website

PRE Investor Relations

Phone: 85222109588

PRENETICS GLOBAL LTD-CL A / PRE FAQ

What is the stock price of PRENETICS GLOBAL LTD-CL A today?

The current stock price of PRE is 5.3877 USD. The price increased by 3.81% in the last trading session.


What is the ticker symbol for PRENETICS GLOBAL LTD-CL A stock?

The exchange symbol of PRENETICS GLOBAL LTD-CL A is PRE and it is listed on the Nasdaq exchange.


On which exchange is PRE stock listed?

PRE stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PRENETICS GLOBAL LTD-CL A stock?

5 analysts have analysed PRE and the average price target is 9.18 USD. This implies a price increase of 70.39% is expected in the next year compared to the current price of 5.3877. Check the PRENETICS GLOBAL LTD-CL A stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PRENETICS GLOBAL LTD-CL A worth?

PRENETICS GLOBAL LTD-CL A (PRE) has a market capitalization of 65.84M USD. This makes PRE a Micro Cap stock.


How many employees does PRENETICS GLOBAL LTD-CL A have?

PRENETICS GLOBAL LTD-CL A (PRE) currently has 322 employees.


What are the support and resistance levels for PRENETICS GLOBAL LTD-CL A (PRE) stock?

PRENETICS GLOBAL LTD-CL A (PRE) has a support level at 5.38 and a resistance level at 5.95. Check the full technical report for a detailed analysis of PRE support and resistance levels.


Is PRENETICS GLOBAL LTD-CL A (PRE) expected to grow?

The Revenue of PRENETICS GLOBAL LTD-CL A (PRE) is expected to decline by -56.61% in the next year. Check the estimates tab for more information on the PRE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PRENETICS GLOBAL LTD-CL A (PRE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PRENETICS GLOBAL LTD-CL A (PRE) stock pay dividends?

PRE does not pay a dividend.


What is the Price/Earnings (PE) ratio of PRENETICS GLOBAL LTD-CL A (PRE)?

PRENETICS GLOBAL LTD-CL A (PRE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.2).


What is the Short Interest ratio of PRENETICS GLOBAL LTD-CL A (PRE) stock?

The outstanding short interest for PRENETICS GLOBAL LTD-CL A (PRE) is 0.46% of its float. Check the ownership tab for more information on the PRE short interest.


PRE Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to PRE. When comparing the yearly performance of all stocks, PRE turns out to be only a medium performer in the overall market: it outperformed 53.55% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PRE Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to PRE. While PRE seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PRE Financial Highlights

Over the last trailing twelve months PRE reported a non-GAAP Earnings per Share(EPS) of -4.2. The EPS increased by 85.17% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -25.5%
ROE -31.41%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-950%
Sales Q2Q%59.86%
EPS 1Y (TTM)85.17%
Revenue 1Y (TTM)-92.12%

PRE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to PRE. The Buy consensus is the average rating of analysts ratings from 5 analysts.

For the next year, analysts expect an EPS growth of 20.64% and a revenue growth -56.61% for PRE


Ownership
Inst Owners13.5%
Ins Owners15.63%
Short Float %0.46%
Short Ratio4.9
Analysts
Analysts80
Price Target9.18 (70.39%)
EPS Next Y20.64%
Revenue Next Year-56.61%